MVRIX's research paper on Navibody technology has been published in ACS Nano once again after one year.

This study is an example of MVRIX’s targeted delivery-based mRNA therapeutic design capabilities being effectively implemented in a collaborative research environment, demonstrating the potential for the expansion of the Navibody™ platform into cancer vaccines and next-generation mRNA therapeutics.